Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Three-Session therapy rival CBT for Event-Related depression?

NCT ID NCT07738146

Symptom relief Sponsor: Painhunting LLP Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This pilot trial tests whether a new short therapy, called Painhunting Therapy, can ease depression symptoms as well as standard cognitive behavioural therapy (CBT) in adults whose depression is linked to a stressful life event. Around 60 adults with depressive symptoms will be randomly assigned to receive either Painhunting Therapy (3 to 6 sessions) or CBT (6 to 8 sessions). The main measure is depression severity six weeks after starting treatment, with follow-up at 10 to 12 weeks to see if any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Painhunting Therapy, a structured psychotherapeutic intervention targeting event-related distress, delivered in 3 to 6 sessions
What this could lead to
If effective, Painhunting Therapy could offer a shorter, targeted talk therapy option for depression triggered by stressful life events, potentially easing symptoms in just a few sessions.
What could go wrong
This is a small pilot study, so results may not be definitive or generalizable. The therapy is new and unproven, and its benefit over established CBT remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * PHQ-9 score of 9 or greater at screening. * At least one adverse life event within the prior 24 months, documented using the Life Events Threshold (LTE) instrument. * Resident of Kazakhstan. * Fluent in Russian. * Capacity to provide written informed consent. * Willing to attend at least six sessions within the protocol treatment schedule. Exclusion Criteria: * Active suicidal ideation requiring immediate referral, defined as PHQ-9 item 9 score of 3 or clinical judgment of imminent risk. * Active psychosis or mania. * Active substance use disorder meeting DSM criteria. * Current psychotherapy with another provider. * Initiation of pharmacotherapy within the prior four weeks. * Pre-existing stable antidepressant monotherapy unchanged for eight weeks or longer is permitted. * Inability to provide informed consent in Russian.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression - major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression - major depressive disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Central Painhunting Office

    Astana, Astana, 010000, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.